Literature DB >> 11440408

Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis.

M McCloskey1, J McCaughan, A O Redmond, J S Elborn.   

Abstract

BACKGROUND: Respiratory disease is the major cause of morbidity and mortality in cystic fibrosis (CF). The significance of Burkholderia cepacia (B. cepacia) in the pathogenesis of lung disease in CF is debated, but its exact role remains unclear. AIM: To assess the impact of respiratory tract colonisation with B. cepacia in patients with CF by measuring changes in pulmonary function and body mass index (BMI).
METHODS: Three groups of patients were defined based on sputum culture isolates: Group 1 were B. cepacia and Pseudomonas aeruginosa (P. aeruginosa) positive patients; Group 2 were P. aeruginosa positive; and Group 3 were colonised with neither organism. Forced expiratory volume (FEV) and BMI were measured annually from 1987 to 1995 and the year of acquisition of P. aeruginosa or B. cepacia was recorded.
RESULTS: The mean annual decrease in FEV1 was significantly different in all three groups: Group 1, -5.4 (5.1)%; Group 2, -3.9 (6.5)%; and Group 3, -1.6 (1.0)%, (p<0.05). The mean percentage decrease in FEV1 of a sub-group of Group 1 patients where the B. cepacia acquisition date was known was 6.1% per year versus 1.55% in Group 2 patients (p<0.05).
CONCLUSIONS: Acquisition of B. cepacia may be a cause of, rather than a marker for, a decrease in pulmonary function.

Entities:  

Mesh:

Year:  2001        PMID: 11440408     DOI: 10.1007/BF03167716

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   2.089


  20 in total

1.  Pseudomonas cepacia--more than a harmless commensal?

Authors: 
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

2.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

3.  Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis.

Authors:  M L Wilsher; J Kolbe; A J Morris; D F Welch
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

4.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

5.  Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients.

Authors:  Y Yamagishi; J Fujita; K Takigawa; K Negayama; T Nakazawa; J Takahara
Journal:  Chest       Date:  1993-06       Impact factor: 9.410

6.  Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.

Authors:  G Gladman; P J Connor; R F Williams; T J David
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

Review 7.  Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology.

Authors:  D A Goldmann; J D Klinger
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

8.  Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis.

Authors:  H Humphreys; D Peckham; P Patel; A Knox
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

9.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.

Authors:  O C Tablan; T L Chorba; D V Schidlow; J W White; K A Hardy; P H Gilligan; W M Morgan; L A Carson; W J Martone; J M Jason
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406

10.  Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.

Authors:  K Muhdi; F P Edenborough; L Gumery; S O'Hickey; E G Smith; D L Smith; D E Stableforth
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

View more
  11 in total

1.  Fatal outcome of lung transplantation in cystic fibrosis patients due to small-colony variants of the Burkholderia cepacia complex.

Authors:  S Häussler; C Lehmann; C Breselge; M Rohde; M Classen; B Tümmler; P Vandamme; I Steinmetz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-28       Impact factor: 3.267

2.  Depletion of the ubiquitin-binding adaptor molecule SQSTM1/p62 from macrophages harboring cftr ΔF508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery.

Authors:  Basant A Abdulrahman; Arwa Abu Khweek; Anwari Akhter; Kyle Caution; Mia Tazi; Hoda Hassan; Yucheng Zhang; Patrick D Rowland; Sankalp Malhotra; Famke Aeffner; Ian C Davis; Miguel A Valvano; Amal O Amer
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

3.  Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis.

Authors:  Basant A Abdulrahman; Arwa Abu Khweek; Anwari Akhter; Kyle Caution; Sheetal Kotrange; Dalia H A Abdelaziz; Christie Newland; Roberto Rosales-Reyes; Benjamin Kopp; Karen McCoy; Richard Montione; Larry S Schlesinger; Mikhail A Gavrilin; Mark D Wewers; Miguel A Valvano; Amal O Amer
Journal:  Autophagy       Date:  2011-11-01       Impact factor: 16.016

4.  Host Adaptation Predisposes Pseudomonas aeruginosa to Type VI Secretion System-Mediated Predation by the Burkholderia cepacia Complex.

Authors:  Andrew I Perault; Courtney E Chandler; David A Rasko; Robert K Ernst; Matthew C Wolfgang; Peggy A Cotter
Journal:  Cell Host Microbe       Date:  2020-08-04       Impact factor: 21.023

5.  Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre.

Authors:  Cassiana da Costa Ferreira Leite; Tania Wrobel Folescu; Mônica de Cássia Firmida; Renata Wrobel Folescu Cohen; Robson Souza Leão; Flávia Alvim Dutra de Freitas; Rodolpho Mattos Albano; Claudia Henrique da Costa; Elizabeth Andrade Marques
Journal:  BMC Pulm Med       Date:  2017-07-14       Impact factor: 3.317

6.  Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.

Authors:  Vidya P Narayanaswamy; Scott Giatpaiboon; Shenda M Baker; William P Wiesmann; John J LiPuma; Stacy M Townsend
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

7.  An Oxygen-Sensing Two-Component System in the Burkholderia cepacia Complex Regulates Biofilm, Intracellular Invasion, and Pathogenicity.

Authors:  Matthew M Schaefers; Tiffany L Liao; Nicole M Boisvert; Damien Roux; Deborah Yoder-Himes; Gregory P Priebe
Journal:  PLoS Pathog       Date:  2017-01-03       Impact factor: 6.823

8.  Susceptibility of Caenorhabditis elegans to Burkholderia infection depends on prior diet and secreted bacterial attractants.

Authors:  Vaughn S Cooper; Wendy A Carlson; John J Lipuma
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

9.  Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response.

Authors:  Alessandra Bragonzi; Ilaria Farulla; Moira Paroni; Kate B Twomey; Luisa Pirone; Nicola Ivan Lorè; Irene Bianconi; Claudia Dalmastri; Robert P Ryan; Annamaria Bevivino
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Burkholderia cepacia complex: clinical course in cystic fibrosis patients.

Authors:  Tania Wrobel Folescu; Claudia Henrique da Costa; Renata Wrobel Folescu Cohen; Orlando Carlos da Conceição Neto; Rodolpho Mattos Albano; Elizabeth Andrade Marques
Journal:  BMC Pulm Med       Date:  2015-12-08       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.